



Version of attached le:
proof
Peer-review status of attached le:
Peer-reviewed
Citation for published item:
von Grabowiecki, Yanncik and Phatak, Vinaya and Aschauer, Lydia and Muller, Patricia AJ (2021)
'Rab11-FIP1/RCP functions as a major signalling hub in the oncogenic roles of mutant p53 in cancer.',
Frontiers in Oncology, 11 . p. 804107.
Further information on publisher's website:
https://doi.org/10.3389/fonc.2021.804107
Publisher's copyright statement:
Copyright c© 2021 von Grabowiecki, Phatak, Aschauer and Muller. This is an openaccess article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in
this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-prot purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
https://dro.dur.ac.uk
Author’s Proof
Before checking your proof, please read the instructions below
• Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools (Adobe Help).
• Provide your corrections in a single PDF file or post your comments in the Production Forum making sure to reference the relevant query/line
number. Upload or post all your corrections directly in the Production Forum to avoid any comments being missed.
• We do not accept corrections in the form of edited manuscripts nor via email.
• Do not provide scanned or handwritten corrections.
• Before you submit your corrections, please make sure that you have checked your proof carefully as once you approve it, you won’t be able
to make any further corrections.
• To ensure the timely publication of your article, please submit the corrections within 48 hours. After submitting, do not email or query asking
for confirmation of receipt.
Do you need help? Visit our Production Help Center for more information. If you can’t find an answer to your
question, contact your Production team directly by posting in the Production Forum.
Quick Check-List
☐ Author names - Complete, accurate and consistent with your previous publications
☐ Affiliations - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country
☐ Tables - Make sure our formatting style did not change the meaning/alignment of your Tables.
☐ Figures - Make sure we are using the latest versions.
☐ Funding and Acknowledgments - List all relevant funders and acknowledgments.
☐ Conflict of Interest - Ensure any relevant conflicts are declared.
☐ Supplementary files - Ensure the latest files are published and that no line numbers and tracked changes are visible.
Also, the supplementary files should be cited in the article body text.
☐ Queries - Reply to all typesetters queries below
☐ Content - Read all content carefully and ensure any necessary corrections are made.
Author Queries Form
Q1 Confirm whether the insertion of the article title is correct.
Q2 The citation and surnames of all of the authors have been highlighted. Check that
they are correct and consistent with the authors' previous publications, and correct
if need be. Please note that this may affect the indexing of your article in repositories
such as PubMed.
Q3 Confirm that the email address in your correspondence section is accurate.
Q4 Please ask the following authors to register with Frontiers (at https://www.frontiersin.
org/Registration/Register.aspx) if they would like their LOOP profile to be linked to
the final published version. Please ensure to provide us with the profile link(s) when
submitting the proof corrections. Non-registered authors and authors with profiles
set to private mode will have the default profile image displayed.
“Vinaya Phatak”
“Lydia Aschauer”
“Patricia A. J. Muller”
Q5 There is a discrepancy between the styling of the author names in the submission
system and the manuscript. We have used "Patricia A. J. Muller" instead of "Patricia
Anthonia Johanna Muller". Please confirm that it is correct.
Q6 Confirm that all author affiliations are correctly listed. Note that affiliations are listed
sequentially as per journal style and requests for non-sequential listing will not be
applied. Note that affiliations should reflect those at the time during which the work
was undertaken.
Q7 Provide the expanded form of "UK".
Q8 Provide the department details for Affiliations 2-4 .
Q9 Provide the expanded form of "MRC".
Q10 Confirm that the keywords are correct and keep them to a maximum of eight and a
minimum of five. (Note: a keyword can be comprised of one or more words.) Note
that we have used the keywords provided at Submission. If this is not the latest
version, please let us know.
Q11 Confirm that the short running title is correct, making sure to keep it to a maximum
of five words.
Q12 Check if the section headers (i.e., section leveling) were correctly captured.
Q13 If you decide to use previously published, copyrighted figures in your article, please
keep in mind that it is your responsibility, as the author, to obtain the appropriate
permissions and licenses and to follow any citation instructions requested by third-
party rights holders. If obtaining the reproduction rights involves the payment of a
fee, these charges are to be paid by the authors.
Q14 Ensure that all the figures, tables and captions are correct, and that all figures are of
the highest quality/resolution. Please note that Figures and Tables must be cited
sequentially, as per section 2.2 of the author guidelines
Q15 Verify that all the equations and special characters are displayed correctly.
Q16 Confirm that the Data Availability statement is accurate. Note that we have used the
statement provided at Submission. If this is not the latest version, please let
us know.
Q17 Ensure to add all grant numbers and funding information, as after publication this will
no longer be possible. All funders should be credited and all grant numbers should
be correctly included in this section.
Q18 Ensure that any supplementary material is correctly published at this link:
https://www.frontiersin.org/articles/10.3389/fonc.2021.804107/full#supplementary-
material
If the link does not work, you can check the file(s) directly in the production forum;
the published supplementary files appear in green.
Provide new files if you have any corrections and make sure all Supplementary files
are cited. Please also provide captions for these files, if relevant.
Frontiers will deposit ALL supplementary files to FigShare and they will receive a
DOI.
Notify us of any previously deposited material.
If the Supplementary Material files contain identifiable images, please keep in mind
that it is your responsibility, as the author, to ensure you have permission to use the
images in the article. Please check this link for author's responsibility for publication
of identifiable images.
Q19 Confirm that the details in the “Author Contributions” section are correct and note
that we have added the sentence “All authors contributed to the article and
approved the submitted version.”
Q20 Frontiers guidelines require listing the first 6 authors + et al. for articles with more
than 6 authors. Please provide the names of the other 6 authors for the following
references. 1, 5, 6, 8, 10–14, 16–18, 20, 22, 23, 25, 26, 28–30, 32, 33, 35, 37, 39–
41, 45, 50, 51, 54, 56–59 and 64–67.
Q21 Provide the volume number and page range for the following reference. 26.
Q22 Provide the page range for the following references. 34, 55, 60 and 62.
Q23 Confirm if the text included in the Conflict of Interest statement is correct.
Q24 Please provide the doi for 50.
Q25 The references have been renumbered sequentially to conform to
Frontiers’ requirements.
Q1Rab11-FIP1/RCP Functions
as a Major Signalling Hub
in the Oncogenic Roles of
Mutant p53 in Cancer
Yannick von Grabowiecki1 Q2 Q4
Q5
, Vinaya Phatak2,3, Lydia Aschauer2,4
and Patricia A. J. Muller1,5*
1 Q7 Q6Tumour Suppressors Group, Cancer Research UK Manchester Institute, The University of Manchester,
Macclesfield, United Kingdom, 2 Q8 Q9MRC Toxicology Unit, Cambridge, United Kingdom, 3 Avacta Life Sciences,
Cambridge, United Kingdom, 4 Orbit Discovery, Oxford, United Kingdom, 5 Department of Biosciences, Faculty of Science,
Durham University, Durham, United Kingdom
Rab11-FIP1 is a Rab effector protein that is involved in endosomal recycling and trafficking
of various molecules throughout the endocytic compartments of the cell. The
consequence of this can be increased secretion or increased membrane expression of
those molecules. In general, expression of Rab11-FIP1 coincides with more tumourigenic
and metastatic cell behaviour. Rab11-FIP1 can work in concert with oncogenes such as
mutant p53, but has also been speculated to be an oncogene in its own right. In this
perspective, we will discuss and speculate upon our observations that mutant p53
promotes Rab11-FIP1 function to not only promote invasive behaviour, but also
chemoresistance by regulating a multitude of different proteins.
Keywords: Q10Rab11-FIP1, RCP, p53, recycling, cancer, integrin, invasion, metastasis
INTRODUCTION Q12
Rab11-FIP1 was identified as a downstream effector and interactor of the Rab-GTPase Rab11a,
important in membrane recycling systems (1). Rab GTPases form a family of more than 70
members, regulating vesicle trafficking in different cell localisations or compartments (2–4), and
cycle between a membrane-bound state (bound to GTP) and a cytosolic state (free of GTP). Rab11
specifically, has been shown active and involved in endocytosis, recycling compartments and the
trans-golgi network, regulating endocytic membrane traffic. When bound to GTP, Rab11 interacts
with Rab11-FIP1 in the early endosomal recycling compartment (5). Rab11-FIP1 is required for
endosomal recycling, and regulates the sorting of proteins into endosomes and the delivery of cargo
to the plasma membrane (6, 7). Its cargo can be diverse and includes receptor tyrosine kinases,
Abbreviations: Akt, Protein Kinase B; ATP7B, Copper-transporting ATPase 2; DGK- a, Diacylglycerol Kinase alpha; EGF/
EGFR, Epidermal Growth Factor (Receptor); FAK, Focal Adhesion Kinase 1; FHOD3, Formin Homology 2 Domain
Containing 3; HGF/HGFR, Hepatocyte Growth Factor (Receptor); IGF2R, Insulin Like Growth Factor 2 Receptor; LMTK3,
Lemur Tyrosine Kinase 3; MARK2, Microtubule Affinity Regulating Kinase 2; MT1-MMP, Membrane-Type 1 Matrix
Metalloproteinase; P-gp, P-glycoprotein; PDGFR, Platelet-Derived Growth Factor Receptor; Rab11-FIP1, Rab11 Family-
Interacting Protein 1; RCP, Rab Coupling Protein; ROCK, Rho-associated Protein Kinase; RTK, Receptor Tyrosine Kinase;
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integrins and other membrane receptors or molecules
schematically depicted in Figure 1 and discussed below.
Based on the frequent overexpression of Rab11-FIP1 in
cancers (overexpression or amplified 8p11–12 amplicon),
Rab11-FIP1 was proposed to be an oncogene (8, 9).
Importantly, Rab11-FIP1 can drive metastasis in vivo, which
was demonstrated using a pancreatic ductal adenocarcinoma
mouse model harbouring pancreas-specific p53 and K-Ras
mutations. In this context, loss of Rab11-FIP1 reduced the
overall metastatic burden (10). In contrast, some data suggest
that loss of Rab11-FIP1 promotes oncogenesis or invasion in
cervical or oesophageal cancers (11, 12). Rab11-FIP1 can
therefore not be classed as an oncogene in its own right yet. It
is possible that increased Rab11-FIP1 function or expression is
context-dependent and enhanced by the presence of oncogenes,
including mutant p53, or by a tumour promoting environment
in which cytokines, integrins and growth factors such as EGF are
enriched (13).
MUTANT p53 AND THE ROLE OF RAB11-
FIP1 IN INTEGRIN/RTK SIGNALLING
p53 is a transcription factor involved in many different processes,
including cell death and senescence. By reacting to incoming
stresses, p53 activates specific transcriptional programmes, such
as apoptosis or cell cycle arrest. This allows the organism to stop
further accumulation of DNA damage and allows for DNA
repair or cell death depending on the amount of stress.
Mutations in TP53 can lead to loss of p53 protein expression or
in about 75% of cases, to the expression of a mutant p53 protein
(14). Mutant p53 expression results in loss of the tumour
suppressor function as well as acquisition of a gain-of-function
that promotes proliferation, invasion, metastasis or
chemoresistance. Proposed mechanisms for gain-of-function
include binding to new response elements on the DNA and the
interaction with many different proteins, including transcription
factors such as the p53 family member p63 (15). We have shown
previously that mutant p53 inhibits TAp63a Q15function, and in those
same conditions, mutant p53 promotes the interaction between
integrins, RTKs and the Rab-coupling protein/Rab11-Family
Interacting Protein 1 (RCP/Rab11-FIP1), leading to increased
invasion, cell scattering, metastasis and chemoresistance (16–18).
Integrins form a family of glycoprotein cell surface receptors
that interact with the microenvironment. By binding to
extracellular ligands, they promote adhesion to the extracellular
matrix, other cells or activate intracellular signalling pathways that
are shared and interconnected with receptor tyrosine kinases
(RTKs) (19). Integrins are thus involved in a range of cellular
processes that promote tumorigenesis and confer a survival
advantage to cancer cells. RTKs are cell surface receptors that
bind to growth factors, hormones and cytokines to promote cell
signalling mediated through their inherent tyrosine kinase activity.
The integrin/RTK cooperation amplifies signalling, promoting
tumour formation, aggressiveness and drug resistance.
We and others have shown that the cooperation of integrin b5
and EGFR is dependent on Rab11-FIP1 (13, 16, 20, 21). In some
cells, this was dependent on stimulation with the EGFR ligand
EGF, or with the avb3 integrin ligand osteopontin (13).
However, when mutant p53 was expressed, osteopontin
activation was not required to induce Rab11-FIP1-dependent
delivery of integrins and EGFR to the plasma membrane (16).
Downstream of EGFR and integrins, the Akt/PKB pathway and
its substrate RacGAP1 were activated (22). Activation of
RacGap1 lead to the repression of cytoskeleton regulator Rac1,
promotion of RhoA activity and cytoskeleton re-organisation to
extend pseudopodial protrusions with actin spikes, leading to
increased invasion (22). These actin spike extensions depended
on activation of the protein FHOD3 by ROCK (23). Part of the
role of Rab11-FIP1 in the pseudopodia is dependent on
diacylglycerol kinase a (DGK-a) (24). DGK-a phosphorylates
diacylglycerol to phosphatidic acid (25). Rab11-FIP1 can interact
FIGURE 1 |Q13
Q14
Mutant p53 regulates RAB11-FIP1-dependent re-localisation of a variety of proteins. Mutant p53 can regulate RAB11-FIP1 by inhibiting the p53 family
member p63 and/or the downstream target Dicer. Rab11-FIP1 enhances the re-localisation of a variety of proteins indicated in this figure. * indicates mutant p53
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with phosphatidic acid resulting in the mobilisation of Rab11-
FIP1 into the pseudopodia of the cells.
Beside regulating EGFR, we have more recently demonstrated
that mutant p53 also promotes the association of Rab11-FIP1
with c-Met (HGFR, hepatocyte growth factor receptor) (26). This
interaction promoted the scattering of cells and increased
pERK1/2 signalling, contributing to HGF-mediated invasion.
To a large extent, all these interactions were dependent on the
p53 family member TAp63a and its target gene, the microRNA
machinery protein Dicer (27). Combined integrin-RTK
signalling is thought to amplify signalling to the Erk1/2 and
Akt proteins, driving enhanced invasion, cell scattering and
metastasis (16, 17).
As we demonstrated that mutant p53 through Rab11-FIP1
could promote recycling of both EGFR and c-Met, it is tempting
to consider that other RTKs are regulated in this manner. Likely
candidates could be EphA2, IGF2R, PDGFR and VEGFR. EphA2
has been shown to bind to Rab11-FIP1 to mediate metastasis in
vivo. In response to HGF, Akt phosphorylates EphA2. In parallel,
HGF promotes phosphorylation of Rab11-FIP1 by the Lemur
tyrosine kinase-3 (LMTK3) leading to EphA2 binding and
plasma membrane expression. This results in cell-cell
repulsion, driving metastatic behaviour (10). However, an
involvement of mutant p53 was not demonstrated and remains
to be elucidated. IGF2R, PDGFR and VEGFR have all been found
transcriptionally regulated by GOF mutant p53 (28–31),
although a connection with Rab11-FIP1 has not yet been
established. Perhaps by both regulating expression as well as
actual plasma membrane expression, something that is likely also
occurring for b1 integrin (32), mutant p53 could facilitate an
amplified cell signalling response that promotes metastastic
behaviour and causes the multidrug chemoresistance that is
often seen in mutant p53 tumours.
Taken together, these data demonstrate that mutant p53 can
regulate integrin/RTK signalling in a Rab11-FIP1-dependent
manner to promote invasion and metastasis.
MUTANT p53, RAB11, RAB11-FIP1 AND
OTHER MECHANISMS PROMOTING
INVASION AND METASTASIS
Interestingly, mutant p53 was also shown to promote invasion
and metastasis by modifying the secretome of cells in a Rab11-
FIP1-dependent manner (33, 34). Novo et al. demonstrated that
mutant p53 cells with upregulated Rab11-FIP1 are able to
influence the phenotype of distant cells through the production
of podocalyxin-containing exosomes. These exosomes then
remodel the extracellular matrix, supporting invasion of the
mutant p53 cells through upregulated Rab11-FIP1 and,
notably, a5b1 integrin, c-Met and Transferrin Receptor (TfnR)
recycling in neighbouring wildtype p53 or p53-null cells (33).
Additionally, Zhang et al. propose a model in which mutant
p53 promotes the vesicular trafficking and secretion of the
Hsp90a chaperone in a Rab11-FIP1 dependent manner (35)
(Figure 1). HSP90a secretion occurs at least in some tumours
and cancer cell lines (36–38) and is known to promote
tumorigenesis (39–41). The Hsp90a interaction with
extracellular matrix proteins and receptors is thought to
underlie matrix remodelling and increased invasion and
metastasis of mutant p53 cells (35).
In conclusion, these data suggest that Rab11-FIP1 can also act
over longer distances through cargo exosome secretion to
promote invasion and metastasis.
MUTANT p53 AND RAB11-FIP1 IN
CHEMORESISTANCE
It has been shown that enhanced integrin signalling confers
resistance against several chemotherapeutic compounds (42–44).
In cultured lung adenocarcinoma A549 cells, Rab11-FIP1-
mediated b1 integrin recycling and signalling was able to
confer resistance to cisplatin (45). Various others have shown
that increased activation of RTKs via integrins confers
chemoresistance through RTK signalling (44, 46). As mutant
p53 promotes chemoresistance (47–49), it therefore seemed
likely that mutant p53 could promote chemoresistance through
the Rab11-FIP1/integrin/EGFR signalling pathway. Indeed, cells
in which we knocked-out Rab11-FIP1 appeared to become more
sensitive to etoposide and cisplatin (18). However, when
inhibiting integrins, the sensitivity was less pronounced
compared to loss of Rab11-FIP1 expression, suggesting
alternative pathways are involved in this chemoresistance (18).
Interestingly, in a screen to detect novel Rab11-FIP1
interacting proteins, we identified the xenobiotic and
chemotherapeutic efflux transporter P-glycoprotein (P-gp/
MDR1) (18) as well as the copper and cisplatin transporter
ATP7B. We could demonstrate that Rab11-FIP1 promoted
membrane localisation of P-gp in response to etoposide and
cisplatin and enhanced efflux of its substrates (18). Its response to
cisplatin is remarkable, as cisplatin is currently not considered a
substrate of P-gp. These data suggest a generic response to
chemotherapeutics that promotes plasma membrane
localisation of Rab11-FIP1 and its cargo (18).
ATP7B is a transmembrane protein which translocates from
the Golgi apparatus to the plasma membrane in response to
copper overload. Through a copper binding domain, ATP7B
binds copper and facilitates efflux of excess copper. However, this
binding domain is also responsible for the efflux of cisplatin,
which could suggest a role for Rab11-FIP1/mutant p53 in
promoting cisplatin efflux through this receptor. The Rab11-
FIP1/ATP7B interaction was validated in independent
immunoprecipitations in A431 cells exogenously (Figure 2A)
and endogenously (Figure 2B) and both proteins colocalise in
cells in the Golgi/vesicular compartment (Figure 2C). Similar to
P-gp, ATP7B accumulated on the plasma membrane of mutant
p53 cells in response to cisplatin, but to a lesser extent in Rab11-
FIP1 KO cells (Figure 2D). These data suggest that in response
to cisplatin, Rab11-FIP1 assists the re-localisation of ATP7B to
the plasma membrane. Remarkably, loss of Rab11-FIP1 appeared
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membrane in response to copper (Figure 2D) and Rab11-FIP1
KO cells were not more sensitive to copper exposure (Figure 2E).
These data could indicate that the type of external stimulus (in
this case chemotherapeutics, but not copper) dictates Rab11-
FIP1 activity.
Interesting from the aspect of chemoresistance is the role of
Rab11 in starvation-induced autophagy. Autophagy is known to
play a major role in chemoresistance and Rab11 was shown to be
required for autophagosome assembly (50). In response to
starvation, Rab11 is relocated from recycling endosomes to
autophagosomes (51). Mutant p53 is known to inhibit
autophagy, but can also itself be targeted for degradation in
response to starvation signals (51). It will be interesting to see if
the decrease in mutant p53 expression changes the interaction of
Rab11-FIP1 with Rab11 and whether this leads to a





FIGURE 2 | Mutant p53 promotes ATP7B plasma membrane expression in a Rab11-FIP1 dependent manner upon cisplatin stimulation. (A) A431 cells expressing
mutant p53 (R273H) were transfected to express GFP or GFP-Rab11-FIP1. GFP was immunoprecipitated and co-immunoprecipitation was assessed through
western blot, using an ATP7B antibody. (B) Co-immunoprecipitation of endogenous ATP7B with Rab11-FIP1 in mutant p53 A431 cells expressing GFP-ATP7B or a
GFP control. ATP7B was immunoprecipitated followed by western blot to detect Rab11-FIP1 binding. (C) Co-localisation of endogenous Rab11-FIP1 and GFP-
ATP7B (GFP) was determined using immunofluorescence in A431 cells transfected with GFP-ATP7B (D) A431 control or A431 Rab11-FIP1-KO cells transfected
with GFP-ATP7B were incubated in cisplatin (3µM) or copper (CuSO4, 100µM) for 2 h and assessed for ATP7B localisation. b-catenin was used as membrane
marker and DAPI as nuclear marker. Arrows indicate ATP7B plasma membrane expression. All immunofluorescence experiments were performed in triplicates and
assessed in >25 cells per experiment and observer with single plane confocal imaging. Representative images are shown. (E) A431 control or A431 Rab11-FIP1-KO
cells were incubated in increasing copper concentrations for 72 h and subjected to a resazurin survival assay. Error bars indicate standard deviation of 3
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OTHER MOLECULES REGULATED BY
RAB11-FIP1
Rab11-FIP1 has also been shown to interact or co-localise with
other proteins and receptors including the TfnR, adiponectin,
LRP1B and HIV1 gp160 protein (Figure 1), although the
functional consequences of these associations remain to be
fully elucidated (5, 6, 52–54). Of these, the Rab11-FIP1-
dependent regulation of the TfnR, mostly involved in iron
uptake, has been most thoroughly studied, but whether Rab11-
FIP1 has a role in iron homeostasis is unknown. Interestingly,
mutant p53 cells are likely to have elevated iron levels and
mutant p53 expression is correlated to elevated transferrin
expression (55).
These data could point to a role for Rab11-FIP1 in mediating
several distinct downstream signalling pathways downstream of
mutant p53 and would make Rab11-FIP1 an interesting target
for therapeutic intervention and raises the question of how
Rab11-FIP1 is regulated within the cell.
INTRACELLULAR REGULATION OF
RAB11-FIP1
In many of the previous settings, it appears that Rab11-FIP1
function can be altered dependent on the stimulus impacted
upon cells. In response to EGF, Rab11-FIP1 regulates EGFR
membrane expression and in response to etoposide or cisplatin,
Rab11-FIP1 promotes expression of P-gp and/or ATP7B to the
plasma membrane. Interestingly, Francavilla et al. demonstrated
that EGFR recycling can be dependent on the type of signalling
(20). When stimulated with TGF-a, EGFR recycling occurred in
a Rab11-FIP1 -dependent manner. However, upon EGF
incubation, EGFR was recycled in a Rab7-dependent manner,
itself dependent on phosphorylation.
The activity of Rab11-FIP1 has been shown regulated by
phosphorylation through 2 different kinases so far: Lemur
Tyrosine Kinase 3 (LMTK3) and MAP/Microtubule Affinity-
Regulating Kinase 2 (MARK2).The LMTK3 kinase promotes
S435 phosphorylation of Rab11-FIP1 in response to HGF
stimulation (10) and has been studied for its role in breast
cancer (56).The MARK2 kinase was shown to promote
phosphorylation of S234 in Rab11-FIP1 and promoted
polarization of MDCK cells upon a calcium switch. MARK2 is
overexpressed in cisplatin-resistant cell lines and expression level
of MARK2 correlate with resistance to cisplatin in non-small cell
lung cancer (57). This finding suggests that the increase in
Rab11-FIP1 activity in mutant p53 cells may be mediated by
the MARK2 kinases.
While the activity or expression of these kinases has not
directly been linked to mutant p53 expression, it is easy to
hypothesise that an increase of Rab11-FIP1 activity could be
facilitated through mutant p53-dependent activation of the
aforementioned kinases. Several other kinases such as
MAP2K3 (58), Aurora kinase A (59) and JNK (60) are
regulated by or cooperate with mutant p53. Enhancing the
activity of kinases that phosphorylate Rab11-FIP1 would lead





With Rab11-FIP1 constituting what appears to be a distribution
hub enabling pro-tumorigenic effects through different
processes, it could be an interesting drug target in a mutant
p53 setting, especially given the fact that mutant p53 targeting
therapies are not yet available in the clinic. Several avenues could
be explored and can be divided into therapies targeting Rab11-
FIP1 itself or any of its downstream effector molecules.
In 2005, Marie et al. reported that Rab11-FIP1 is degraded by
calpains in a calcium-dependent manner (61). Increased
intracellular Calcium levels (by using the ionophore
Ionomycin) reduced Rab11-FIP1 levels. Ionophores such as
Ionomycin have been explored as potential anticancer drugs,
and might contribute to apoptosis due to increased calcium levels
in synergy with chemotherapeutics (62). It will be interesting to
explore this strategy in cancers that depend on Rab11-FIP1 and/
or mutant p53 expression.
Another way in which Rab11-FIP1 expression levels can be
regulated is by the microRNA miR-93. Rab11-FIP1 is a direct
target, as demonstrated in cervical cancers in which elevated
miR-93 levels coincide with reduced Rab11-FIP1 levels (11).
Using cultured cells, Zhang et al. showed that the knockdown of
miR-93, allowed for higher Rab11-FIP1 expression, increases
apoptosis and reduces proliferation. In that context, miR-93
knockdown seems an interesting approach to reduce
tumorigenicity by acting on Rab11-FIP1. However, these
findings go against the current “dogma” in the field where
elevated Rab11-FIP1 levels and its activation are tumorigenic
(11) and might therefore indicate a tissue specific effect, making
it pivotal to study Rab11-FIP1’s role in different cancers. In other
cancers, using miR-93-containing constructs as actual
therapeutic could be a strategy now that siRNA therapy has
FDA approval to be used in the clinic (63).
Downstream of Rab11-FIP1, EGFR and/or integrin inhibitors
have been investigated. Resveratrol and curcumin, which are
known to reduce tumour growth, impacted on the expression or
activation of these proteins. In oral squamous cell carcinoma
development and invasion, Rab11-FIP1 upregulated Zeb1, and
subsequently MT1-MMP downstream of b1-integrin/EGFR and
b-catenin signalling. Resveratrol inhibited EGFR activation and
b1 integrin recycling (21). In cultured SKOV-3 and PA-1 ovarian
cancer cells, Rab11-FIP1 promoted invasion by stabilising b1
integrin and activating FAK through EGFR. Interestingly,
Curcumin reduced b1 integrin stability, thus reducing EGFR
and FAK activation, leading to reduced invasion (64). Most
interestingly, resveratrol and curcumin have also been
demonstrated to inhibit tumorigenicity of mutant p53
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cancer cells that Resveratrol inhibits mutant p53 aggregation, but
also cell proliferation and migration, thereby reducing
tumorigenicity (65). Curcumin was able to re-activate mutant
p53 to induce cell death in cultured cells (66, 67), as well as
reduce growth of tumour xenografts (66).
Other inhibitors to consider in this respect are direct EGFR
inhibitors such as Gefitinib, Erlotinib, Panitumumab and
Cetuximab or the integrin inhibitor Cilengitide, which have all
been in clinical trials, with some more successful than others.
Perhaps, those work best in a setting of mutant p53 and Rab11-




In this perspective, we have seen that mutant p53 can regulate
Rab11-FIP1 to modulate a plethora of proteins involved in
tumour formation, invasion, metastasis and chemoresistance.
Any molecule that could inhibit Rab11-FIP1 could therefore
have the potential to stop tumour growth, prevent metastasis and
prevent chemoresistance. Some molecules that inhibit
downstream pathways of Rab11-FIP1 have shown potential,
but strategies that would act on Rab11-FIP1 itself would
presumably be more potent. Of interest are the regulation of
Rab11-FIP1 by calpains and the degradation upon ionomycin
treatment, as well as the potential of targeting Rab11-FIP1 by
siRNA. In order to develop a Rab11-FIP1 -based therapy, more
research will be needed into the regulation of Rab11-FIP1, its
interaction with cargo in different conditions and the cancer-
specificity of this response.
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